This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MLND Millendo Therapeutics (MLND) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Millendo Therapeutics Stock (NASDAQ:MLND) Get Millendo Therapeutics alerts:Sign Up Key Stats Today's Range$1.54▼$1.6150-Day Range$3.06▼$5.8452-Week Range$0.92▼$16.95Volume152,321 shsAverage Volume1.52 million shsMarket Capitalization$29.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan. Read More Receive MLND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Millendo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLND Stock News HeadlinesRelease Therapeutics Secures CHF 3.3 Million in Seed FundingAugust 6, 2024 | tmcnet.comA lifesaving therapy for children with a rare disease is now the world’s most expensive drug, raising questions about accessMarch 20, 2024 | msn.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.July 22 at 1:00 AM | Paradigm Press (Ad)Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulationMarch 7, 2024 | msn.comClearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private PlacementJanuary 11, 2024 | markets.businessinsider.comWhy Is Clearmind Medicine (CMND) Stock Up 50% Today?December 5, 2023 | msn.comMaxim Group Maintains Their Buy Rating on Mind Medicine (MMED)November 6, 2023 | markets.businessinsider.comExpert Ratings for Decibel TherapeuticsMarch 15, 2023 | benzinga.comSee More Headlines MLND Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Millendo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Millendo Therapeutics investors own include Elbit Systems (ESLT), UnitedHealth Group (UNH), AbbVie (ABBV), American Water Works (AWK), Bright Health Group (BHG), Black Hills (BKH) and Blackrock Municipal 2030 Target Term Trust (BTT). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:MLND CIKN/A Webwww.millendo.com Phone734 845 9000FaxN/AEmployees12Year Founded2012Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-91.03% Return on Assets-72.44% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book0.88Miscellaneous Outstanding Shares19,043,000Free FloatN/AMarket Cap$29.71 million OptionableNot Optionable Beta0.48 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:MLND) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredTrump’s emergency dollar resetBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | SponsoredThis could help save your retirementMurray Stahl is a Wall Street money manager who put more than half of his $9 billion firm into a single stock ...Stansberry Research | SponsoredTSM just handed Trump's secretive AI project $100 billionTaiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Millendo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.